Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.

On December 7th, the "National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug List (2025)" was officially announced. Jiangsu Hengrui Pharmaceuticals (01276) has a total of 20 products/indications that have been adjusted in the new national medical insurance list, with 10 products entering medical insurance for the first time. This will continuously improve the accessibility and affordability of high-quality medicines, benefiting a wider range of Chinese patients. 10 products entering medical insurance for the first time This time, Jiangsu Hengrui Pharmaceuticals' 10 products have been included in the new national medical insurance drug list through negotiations, covering various fields such as oncology, metabolism, cardiovascular diseases, autoimmune diseases, ophthalmology, etc. These products are: Avitado (rituximab for injection) Used for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients with HER2 (ERBB2) activating mutations, who have previously received at least one systemic therapy. It is also the first domestically developed antibody-drug conjugate for HER2-mutant NSCLC patients in China. Currently, rituximab has been included in the breakthrough therapy list by the National Medical Products Administration for 9 indications, covering various tumors such as NSCLC, breast cancer, gastric cancer or gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, gynecological malignancies, etc. The combination of rituximab with atezolizumab and chemotherapy for gastric or gastroesophageal junction adenocarcinoma has also been granted orphan drug designation by the FDA in the United States. Aisuda (emetine sulfate tablet) The first domestically developed JAK1 inhibitor in China, the indications included in medical insurance are: adult patients with active ankylosing spondylitis who have inadequate response or intolerance to one or more TNF inhibitors, adult patients with moderate to severe active rheumatoid arthritis who have inadequate response or intolerance to one or more TNF inhibitors, adult patients with moderate to severe atopic dermatitis who have inadequate response or intolerance to topical treatment or other systemic treatment. Andajing (futezumab monoclonal antibody injection) The first domestically developed recombinant anti-IL-17A humanized monoclonal antibody approved in China, used for the treatment of moderate to severe plaque psoriasis in adults suitable for systemic therapy or phototherapy, and adult patients with ankylosing spondylitis who have inadequate response to conventional treatment. With this, the product has had two indications approved, both of which have been included in the medical insurance list. Aixinan (rituximab for injection) The world's first super-long-acting PCSK9 monoclonal antibody, used in combination with statins or with statins and other lipid-lowering therapies, for adults receiving moderate or higher doses of statins but still unable to achieve low-density lipoprotein cholesterol (LDL-C) targets for primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed lipid abnormalities; or as monotherapy for adults with non-familial hypercholesterolemia and mixed lipid abnormalities to lower levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and apolipoprotein B (ApoB). Ruitanin (ralopatam poloronatus chinol) The first super-long-acting original dual-target antiemetic injection in China, used to prevent acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy (HEC) in adults. Ruilin Tang (regletin dimethylbiguanide tablets (I)/(II)) The first domestically developed DPP-4i combined with metformin fixed-dose compound, in combination with dietary control and exercise, is suitable for adults with type 2 diabetes who are suitable for treatment with regletin phosphate and metformin for improving glycemic control. Aibite (apple acid afinitinib capsules) The company's independently developed multi-target tyrosine kinase receptor (RTK) inhibitor, used in combination with cetuximab for the treatment of recurrent or metastatic cervical cancer that has failed prior platinum-based chemotherapy but has not been treated with cetuximab. Aiergie (abiraterone acetate acetate tablets (II)) The first domestically developed abiraterone acetate nano crystal formulation in China, used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including those who have not received hormone therapy or have been on hormone therapy for no more than 3 months. Yueyouli (fluorescent sulfohexylhexane lipid injection (II)) In combination with fluorouracil (5-FU) and calcium folate (LV), it is used for the treatment of unresectable locally advanced or metastatic pancreatic cancer patients who have failed prior gemcitabine-based chemotherapy. Hengqin (perfluorohexylhexane eye drops) Currently the only drug in the world for the treatment of meibomian gland dysfunction (MGD) related dry eyes, providing a new drug treatment option for patients in China with this condition. 5 products with new indications added to medical insurance Jiangsu Hengrui Pharmaceuticals' Class 1 innovative drug Airray (fluzopali capsules), Airka (cetuximab monoclonal antibody injection), Airsut (tegilitine fumarate injection), Aitan (apatinib mesylate tablets) and the first imitation product Aheng Ping (bupivacaine liposome injection) have new indications added to national medical insurance, effectively reducing the economic burden on patients. Airray (fluzopali capsules) is China's first domestically developed PARP inhibitor, with 5 indications approved in the field of advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer, breast cancer. Aitan (apatinib mesylate tablets) is a small molecule tyrosine kinase inhibitor targeting VEGFR developed by the company, with 4 indications approved in gastric cancer, liver cancer, breast cancer. The new indications added this time are: fluzopali capsule monotherapy or in combination with apatinib mesylate for the treatment of adult patients with HER2-negative metastatic breast cancer with germline BRCA mutations (gBRCAm) who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic stage. Hormone receptor (HR)-positive breast cancer patients who have previously received hormonal therapy or are considered unsuitable for hormonal therapy. With this, both indications for the two products have been included in the medical insurance list. Airka (cetuximab monoclonal antibody injection) is a company-developed and proprietary humanized PD-1 monoclonal antibody, with multiple indications approved in lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer, cervical cancer, and other tumor types, making it a leading domestic PD-1 product in terms of approved indications and covered tumor types. The new indication added this time is: combination with apple acid afinitinib for the treatment of recurrent or metastatic cervical cancer patients who have failed prior platinum-based chemotherapy but have not received treatment with cetuximab. With this, the product's approved indications have all been included in the medical insurance list. Aisute (tegilitine fumarate injection) is the first domestically developed selective -opioid receptor agonist in China, previously entered the national medical insurance list for the treatment of moderate to severe pain after abdominal surgery. The new indication added this time is: used for the treatment of moderate to severe pain after orthopedic surgery. Currently, the two indications are uniformly combined and described as "used for the treatment of moderate to severe pain after surgery," fully included in the national medical insurance. Aheng Ping (bupivacaine liposomal injection) is the first generic drug approved for marketing globally. The new indication added this time is: used for postoperative regional analgesia of adults with sciatic nerve block in the popliteal fossa, and postoperative regional analgesia of adults. With this, all approved indications for the product have been included in the medical insurance list. 5 products complete renewal in the list The company's innovative drugs, Airreni (malic acid pyridoxal tablet), Hengqu (heptopapapata ethandolamine tablet), Ruizen (regeratin tablet), Rebening (methasone ritomorphotazarin injection), and Aidou (sulfopyrafezantine injection) have successfully renewed and remain in the national medical insurance list. Ms. Feng Ji, President and Chief Operating Officer of Jiangsu Hengrui Pharmaceuticals, said, "As an innovative international pharmaceutical company rooted in China, Jiangsu Hengrui Pharmaceuticals has been committed to integrating medicine innovation and social responsibility. This time, 20 products/indications of the company have been adjusted in the national medical insurance list, with 10 products entering medical insurance for the first time, which will promote the benefits of Hengrui's innovative therapies to more patients. In the future, we will continue to adhere to the original intention of "putting patients first," accelerate the research and development and market launch of cutting-edge drugs, actively respond to national policies, and strive to improve the accessibility and affordability of patient medication, to help the implementation of the "Healthy China 2030" strategy with practical actions and safeguard national health."